Cystic Fibrosis Trial, Recruiting NCT06504589 Sponsor: Nicole Hamblett Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT06504589
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You (or your legal guardian) are willing and able to sign a consent form agreeing to take part in the study
  • You are willing and able to attend all scheduled study visits and follow the study requirements
  • You are 12 years of age or older at your first study visit
  • If you are someone who could become pregnant, you must not be pregnant at the start of the study and must not plan to become pregnant during the 12-month study period
  • You have a confirmed diagnosis of cystic fibrosis (CF), shown by symptoms of CF plus either: a sweat chloride test result of 60 or above, two known CF-causing gene changes, or one known CF-causing gene change plus a second gene change and a sweat result of 30 or above (confirm with trial site)
  • Your health has been stable with no significant changes in the 28 days before your first visit
  • You have never had a lung transplant

Who may not be able to join:

  • You are genetically eligible for a CFTR modulator medication (a specific type of CF treatment) based on approved guidelines, or you have used one within 28 days before your first visit and plan to continue or restart it during the study
  • You have taken any experimental/investigational drug within 90 days before your first visit
  • You are currently taking part in another clinical trial involving an experimental drug or medical device
  • You have started any new long-term medication (such as ibuprofen, azithromycin, or certain inhaled antibiotics) within the 28 days before your first visit
  • You have used antibiotics (by mouth, inhaled, or through a drip) or steroid medicines for breathing/lung symptoms within the 28 days before your first visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Deepika Polineni, MD, MPH, Washington University School of Medicine

Phone: 206-884-1681

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Nicole Hamblett
Registry
ClinicalTrials.gov
Start date
18 September 2024
Est. completion
14 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in ppFEV1 at 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov